EFM
SNDX icon

E Fund Management’s Syndax Pharmaceuticals SNDX Stock Holding History

E Fund Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Sell
13,788
-1,890
-12% -$39.3K 0.01% 376
2026
Q1 		$366K Buy
+15,678
New +$341K 0.01% 346
2025
Q2 		$131K Sell
14,033
-1,998
-12% -$22K 0.01% 371
2025
Q1 		$197K Buy
16,031
+3,428
+27% +$48.4K 0.01% 364
2024
Q4 		$167K Buy
12,603
+1,583
+14% +$27.1K 0.01% 371
2024
Q3 		$212K Buy
11,020
+214
+2% +$4.42K 0.01% 319
2024
Q2 		$222K Sell
10,806
-6,832
-39% -$143K 0.01% 275
2024
Q1 		$420K Sell
17,638
-3,942
-18% -$87.9K 0.03% 199
2023
Q4 		$466K Buy
21,580
+6,986
+48% +$107K 0.03% 174
2023
Q3 		$212K Sell
14,594
-3,433
-19% -$64.9K 0.02% 250
2023
Q2 		$377K Buy
18,027
+1,962
+12% +$40.8K 0.03% 184
2023
Q1 		$339K Buy
16,065
+2,202
+16% +$54.8K 0.02% 208
2022
Q4 		$353K Buy
13,863
+3,799
+38% +$88.6K 0.03% 205
2022
Q3 		$242K Buy
+10,064
New +$226K 0.02% 268

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

E Fund Management's SNDX Position: Q2 2026 in Review

E Fund Management reduced its Syndax Pharmaceuticals (SNDX) stake by 12% in Q2 2026, selling an estimated $39.3K and leaving 13,788 shares worth $301K. The position accounts for 0.01% of the portfolio, ranked #376.

E Fund Management first reported a position in SNDX in Q3 2022 and has held it in 14 quarters since. The position peaked at $466K in Q4 2023. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • E Fund Management held 13,788 shares of Syndax Pharmaceuticals worth $301K as of Q2 2026.
  • E Fund Management sold 1,890 Syndax Pharmaceuticals shares in Q2 2026, an estimated $39.3K.
  • Syndax Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q2 2026, its #376 holding.
  • E Fund Management first reported a position in Syndax Pharmaceuticals in Q3 2022 and has held it in 14 quarters since.
  • E Fund Management's Syndax Pharmaceuticals position peaked at $466K in Q4 2023.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.